|
|
 |
Robert
M. Bennett, MD,
FRCP, FACP
Dr.
Bennett is Professor of Medicine and Nursing Research at Oregon Health and Science University
(OHSU) in Portland, Oregon. He was born and educated in England, and did his
basic rheumatology training with
Professor Eric Bywaters at the Royal
Postgraduate Medical School in London. He has lived in the USA since
1972 and did additional training with Professor Daniel McCarty at the
University of Chicago. He was Chairman of the Division of Arthritis and
Rheumatic Diseases at OHSU for 24 years (1976-2000). Dr. Bennett is
currently the Board Chairman of the International Myopain Society. He is
a past President of the International Myopain Society
and the American
College of Rheumatology Western Region. He and his colleagues developed
the Fibromyalgia Impact Questionnaire in 1993; it is now the most widely
used instrument for measuring disease activity in fibromyalgia patients.
He first reported adult growth hormone [GH] deficiency in a subset
of fibromyalgia patients in 1992 and has subsequently shown the benefits
of GH replacement. He holds patents for the utilization of GH in
fibromyalgia, (US Patent #
5,378,686) chronic fatigue syndrome, rheumatoid arthritis and
polymyalgia rheumatica US Patent #
5,965,520) His bench research involves the molecular
characterization of cell surface DNA receptors (US Patent #
6,602,707). He has
over 400 publications
and has been on the editorial boards of
Pain, Arthritis and Rheumatism, Geriatrics, the Journal of
Musculoskeletal Pain and the Journal of Functional Syndromes. Dr.
Bennett is now retired from patient care, but continues to be actively
involved in research at OHSU.
|
|